CC
ABOS icon

Commodore Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Commodore Capital’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-400,000
Closed -$1.62M – 27
2023
Q1 		$1.62M Sell
400,000
-98,315
-20% -$513K 0.25% 31
2022
Q4 		$2.69M Sell
498,315
-601,685
-55% -$4.04M 0.41% 31
2022
Q3 		$11M Buy
+1,100,000
New +$6.31M 1.77% 18

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital's ABOS Position: Q2 2023 in Review

Commodore Capital sold out of Acumen Pharmaceuticals (ABOS) in Q2 2023, closing a stake of 400,000 shares — an estimated $1.62M sold.

Commodore Capital first reported a position in ABOS in Q3 2022 and held it in 3 quarters. The position peaked at $11M in Q3 2022. 53 funds tracked by Wall St. Rank hold ABOS as of Q2 2023.

  • Commodore Capital reported no remaining Acumen Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Commodore Capital sold 400,000 Acumen Pharmaceuticals shares in Q2 2023, an estimated $1.62M.
  • Commodore Capital first reported a position in Acumen Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Commodore Capital's Acumen Pharmaceuticals position peaked at $11M in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2023.

Based on Commodore Capital's 13F filing for Q2 2023, filed 14 Aug 2023.